Clinical Trial: Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head
Brief Summary:
Topical treatment of mild to moderate actinic keratosis located on the face and head with Solaraze® is known to be a safe and efficient treatment option. However, it is unclear if an expansion of the treatment period to 6 months will increase the rate of complete responses.
Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic keratosis with Solaraze® applied twice daily to the face and head over 3 or 6 months of treatment.
Detailed Summary:
Sponsor: University Hospital Tuebingen
Current Primary Outcome: Histologically controlled complete clearance of the actinic keratosis [ Time Frame: 6 weeks after end of treatment ]
Original Primary Outcome: Histologically controlled complete clearance of the actinic keratosis
Current Secondary Outcome:
Original Secondary Outcome:
- Time to clinically complete response
- Tolerability
- Quality of life
Information By: University Hospital Tuebingen
Dates:
Date Received: September 13, 2005
Date Started: June 2005
Date Completion:
Last Updated: August 18, 2011
Last Verified: March 2009
